GLP-1 RAs & Incretin-based Therapies Competitive Landscape Analysis: Key Developments by 200+ Companies Shaping the Treatment Landscape | DelveInsight

DelveInsight released a comprehensive competitive landscape report on GLP-1 receptor agonists and incretin-based therapies, covering 200+ pipeline drugs from 180+ active players. The report highlights approved drugs like MOUNJARO (tirzepatide) and OZEMPIC (semaglutide), with 30+ therapies in late-stage development and 60+ in mid/early stages. Key indications include obesity, type 2 diabetes, and cardiovascular outcomes. Recent developments include positive Phase III results for retatrutide, survodutide, and other dual/triple agonists from major pharmaceutical companies.

11/11/2026, 1:00 PM • GlobeNewswire

Idiopathic Inflammatory Myositis Market Set for Strong Growth at 16.8% CAGR Through 2036, Driven by Rising Demand for Targeted Therapies | DelveInsight

The Idiopathic Inflammatory Myositis (IIM) market is projected to grow at 16.8% CAGR through 2036, reaching significant expansion driven by rising disease awareness, improved diagnostics, and an expanding pipeline of targeted therapies. The market was valued at USD 714 million across the 7MM in 2025, with the US accounting for 55% of the market. Multiple pharmaceutical companies are advancing investigational treatments addressing unmet medical needs in dermatomyositis, polymyositis, and inclusion body myositis.

11/10/2026, 1:00 PM • GlobeNewswire

Type 2 Diabetes Clinical Trial and Competitive Landscape Analysis: 200+ Key Companies Shaping the Future of Type 2 Diabetes Therapeutics Space | DelveInsight

DelveInsight released a comprehensive report on the Type 2 Diabetes competitive landscape, analyzing 200+ pipeline drugs from 170+ active players. The report highlights recent approvals including Eli Lilly's FOUNDAYO (orforglipron) and Novo Nordisk's once-weekly insulin options, alongside promising pipeline therapies targeting various mechanisms of action. Key developments include positive Phase III results for CagriSema, elecoglipron, and other novel GLP-1 receptor agonists, with approximately 60+ drugs in late-stage development.

11/10/2026, 1:00 PM • GlobeNewswire

Compugen (CGEN) Q3 2026 Earnings Call Transcript

Compugen reported Q3 2026 results with revenue of $3.8 million and net loss of $5.8 million. The company completed enrollment in its MAIA-Ovarian trial for COM701 with data expected by end of Q1 2027. Partnered programs with AstraZeneca (rilvegostomig) and Gilead (GS-0321) continue advancing, with rilvegostomig in 12 Phase III trials. The company introduced UnigenX, expanding its discovery platform into tumor-associated antigens for T-cell engagers. Cash runway extends into 2029 with $117.5 million in cash and equivalents.

11/09/2026, 11:53 AM • The Motley Fool

Amgen Just Gave Its Shareholders Great News

Amgen's cancer drug Imdelltra demonstrated significant efficacy when combined with AstraZeneca's Imfinzi, reducing death risk by 58% in advanced lung cancer patients and extending median survival to 21.1 months versus 12.7 months with Imfinzi alone. With Imdelltra already generating 115% growth and a robust pipeline of 22 double-digit growth products, Amgen's stock may have further upside potential despite its 40% year-to-date gain.

11/02/2026, 12:25 PM • The Motley Fool

2027 Could Finally Be the Year Cancer Is on the Ropes!

Global cancer research is advancing through AI-supported precision medicine, biomarker-guided treatments, and innovative approaches. Anthropic is supporting pediatric cancer care through the PCX program, while companies like AstraZeneca report survival improvements in gastric cancer with sonesitatug vedotin. Researchers in Japan and South Korea are exploring novel approaches including using cancer cells' own chemistry to produce treatments and reprogramming cancer cells toward normal states.

10/29/2026, 9:10 PM • GlobeNewswire

Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer

HUTCHMED announced an expert webcast on November 5, 2026, to discuss Phase III clinical data for savolitinib in MET-driven NSCLC. The SANOVO study showed savolitinib plus TAGRISSO® reduced disease progression/death risk by 44% overall and 55% in high MET overexpression patients. The SAFFRON global Phase III trial demonstrated a 45% reduction in progression risk and 32% reduction in death risk in EGFR-mutated lung cancer after TAGRISSO® progression.

10/26/2026, 8:00 PM • GlobeNewswire

Onco360® Has Been Selected as a National Pharmacy Partner for ZEGFROVY® (sunvozertinib)

Onco360, the nation's leading independent specialty pharmacy, has been selected as a national pharmacy partner by AstraZeneca Pharmaceuticals for Zegfrovy (sunvozertinib), a kinase inhibitor indicated for treating adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations. The partnership expands Onco360's existing relationship with AstraZeneca and leverages its oncology platform to support patient access and care.

10/26/2026, 5:00 PM • GlobeNewswire

Breakfast News: Science Strikes Back at Cancer

Cancer treatment breakthroughs dominate ESMO 2026 conference with multiple drugs showing significant survival gains. U.S. stocks declined amid AI spending concerns and rising oil prices, with the Fed expected to hold rates steady Wednesday. Several Motley Fool-recommended companies report earnings this week including Alphabet, Amazon, and Mastercard. TransDigm's stock decline reflects valuation compression rather than business deterioration.

10/26/2026, 7:30 AM • The Motley Fool

Global Oral Drugs Market is Predicted to Surpass USD 1 Trillion Mark by 2034 | DelveInsight

The global oral drugs market is experiencing steady growth driven by increasing chronic disease prevalence and patient preference for convenient treatment options. The market is projected to grow from USD 1 trillion in 2025 to USD 1.6 trillion by 2034 at a ~6% CAGR. North America leads with 36% market share, while Asia-Pacific is expected to register the fastest growth. Key drivers include advancements in drug delivery technologies, expansion of oral therapies across oncology and other therapeutic areas, and rising pharmaceutical R&D investments.

10/21/2026, 1:00 PM • GlobeNewswire

Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech?

Alnylam Pharmaceuticals has achieved solid profitability with Q2 2026 net income of $164.5 million and revenue growth of 67% year-over-year, yet its stock has plunged over 40% this year. The decline is attributed to a revenue guidance cut for its drug Amvuttra due to demand normalization and investor concerns about a rival drug's clinical setback. However, Wall Street remains bullish with 19 of 23 analysts recommending a buy, citing the company's strong financials, robust product growth, and promising pipeline.

10/21/2026, 4:44 AM • The Motley Fool

Europe Cancer Metabolism Based Therapeutics Market Forecast to 2035 by Modality, Route, Indication, and Therapy Sales | 25.3% CAGR Drives an $8.54 Billion Opportunity

Europe's cancer metabolism-based therapeutics market is projected to grow from $1.12 billion in 2026 to $8.54 billion by 2035, representing a 25.3% CAGR. Growth is driven by Europe's high cancer burden, advances in molecular profiling, precision oncology adoption, and regulatory validation. Small molecules and oral administration routes dominate, with breast cancer and non-small cell lung cancer as leading indications. Key players include AstraZeneca, Bayer, Novartis, Roche, and Servier.

10/02/2026, 4:55 AM • GlobeNewswire

DaltonTx, the decision engine for drug discovery, launches advanced AI-powered antibody discovery platform

DaltonTx announced the launch of advanced antibody discovery capabilities within its Dalton platform, which integrates AI models for antibody design, structure prediction and validation. The platform can evaluate millions of antibody sequences and help researchers identify promising candidates more efficiently by combining AI outputs with experimental data and expert judgment.

10/01/2026, 3:30 AM • GlobeNewswire

Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast - 2036 | Precision Oncology and Radiopharmaceuticals Unlock New Growth Opportunities

The bone metastasis in solid tumors market is expected to expand from 2026-2036 across seven major markets, driven by rising cancer survival rates, improved diagnostics, and growing demand for targeted therapies and radiopharmaceuticals. The market is characterized by established treatments like denosumab and zoledronic acid, with emerging therapies including cabozantinib and radioligand treatments. Key unmet needs include limited disease-modifying therapies, persistent skeletal complications, and lack of validated biomarkers for treatment selection.

09/30/2026, 4:58 AM • GlobeNewswire

HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer

HUTCHMED announced that AstraZeneca has submitted a New Drug Application (NDA) to the FDA for ORPATHYS® (savolitinib) combined with TAGRISSO® (osimertinib) to treat patients with MET-driven EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy. The submission is supported by the SAFFRON Phase III trial, which demonstrated statistically significant improvements in progression-free survival and overall survival compared to platinum-based chemotherapy.

09/28/2026, 8:00 PM • GlobeNewswire